Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting
TORONTO and HOUSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA…
Year: 2022
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
ZUG, Switzerland and BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Five poster presentations to include preclinical data describing new T-cell reprogramming technology being incorporated in…
Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted…
Genenta to Present at Upcoming Scientific and Investor Conferences
MILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA),…
Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company…
IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company…
Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
A poster evaluating comprehensive correlative science findings from the AFM24 monotherapy phase 1 study (AFM24-101)…
ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting
Abstracts highlight Senti Bio’s continued progress in applying gene circuits to improve the cytotoxicity and…
Valitor Announces the Closing of its Series B Financing and Names Steven Lo as Chief Executive Officer
BERKELEY, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering better medicines to…
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
Interim Analysis Planned for Q1 2023 WILMETTE, Ill., Oct. 05, 2022 (GLOBE NEWSWIRE) — Monopar…
Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference
BOTHELL, Wash., Oct. 05, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that…
Beyond Cancer™ to Present Pre-Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2022 SITC Annual Meeting
Abstract titles to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting…
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting
SAN DIEGO, Oct. 05, 2022 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage…
Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Clinical data in nine cancer indications from trial with 264 patients accrued Plenary discussion relating…
Nautilus Biotechnology to Announce Third Quarter 2022 Financial Results on November 1, 2022
SEATTLE, Oct. 05, 2022 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a…
Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages
– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting…
Fountain Therapeutics Congratulates Co-Founder and Executive Chairman Thomas Rando, M.D., Ph.D., for Prestigious NOMIS Distinguished Scientist Award
Ceremony Held Today in Zurich, Switzerland with Presentation by Dr. Rando and Keynote by Nobel…